Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronary Artery Disease: Validation by Quantitative Cardiac MRI Perfusion

Launched by THE UNIVERSITY OF HONG KONG · Jul 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called cardiac shock wave therapy to see if it can help improve blood flow in the heart for people with coronary artery disease (a condition where the heart’s blood vessels are narrowed but not severely blocked). The researchers will use special heart scans (cardiac MRI) to measure how well blood is flowing to the heart muscle and how the heart is working before and after the treatment. The goal is to find out if this therapy can encourage the growth of new blood vessels and improve heart function.

People who might be eligible to join are adults who have symptoms of coronary artery disease but do not have major blockages in their heart vessels and have a heart pumping function that is not severely reduced (left ventricular ejection fraction of 40% or higher). Participants should be able to undergo MRI scans with contrast dye and should not have had a recent heart attack or other serious health issues that would make the study unsafe. If you join, you can expect to have heart scans and receive the shock wave therapy, which is a non-invasive treatment using sound waves aimed at the heart. This study is currently recruiting, and it’s important to discuss with your doctor whether this trial might be a good fit for you.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients with symptoms of coronary artery disease
• • Patients without obstructive coronary artery disease
• • with LVEF not \< 40%.
• Exclusion criteria:
• • Age \< 18 years,
• • Pregnancy or lactation.
• • Contraindication to contrast enhanced stress Cardiac Magnetic Resonance (eg. Estimated GFR \<30ml/min/1.73m2, severe allergy to gadolinium based contrast agent, contraindication to adenosine)
• • Life expectancy \<24 months
• • Haemodynamically unstable
• • Participation in other clinical trial within 6 months of enrollment.
• • Recent myocardial infarction within 6 months.
• • Unable to consent to or perform components of the study.